We report the case of a giant prolactinoma in a 7-year-old boy, which was complicated by unilateral exophthalmos. The initial levels of prolactin (PRL) were about 80,000 µU/ml. Treatment with cabergoline (CAB) resulted in rapid normalization of serum PRL (6 weeks after initiation of treatment) and reduction of tumor size. In particular, magnetic resonance imaging (MRI), which was done 2.5 months after the patient was put on CAB, revealed tremendous improvement with a decrease in the size of the tumor which now showed no extrasellar extension. Subsequent MRI studies demonstrated further improvement. Exophthalmos, anisocoria and visual fields improved. In summary, this patient represents the first report of the therapeutic use of CAB as the primary mode of treatment in a 7-year-old boy with infiltrative giant prolactinoma complicated by unilateral exophthalmos. It is a noninvasive treatment that can preserve and restore vision, as well as pituitary function, and is preferable to surgery or radiation in the treatment of prolactin-secreting macroadenoma in childhood and adolescence.

Keywords:
Macroprolactinoma, Exophthalmos, unilateral, Cabergoline, Bromocriptine, Prolactin, Dopamine agonist
1.
Partington MD, Dudley HD, Laws ER, Scheithauer BW: Pituitary adenomas in childhood and adolescence. Results of transsphenoidal surgery. J Neurosurg 1994;80:209–216.
2.
Yazigi RA, Quintero CH, Salameh WA: Prolactin disorders. Fertil Steril 1997;67:215–225.
3.
Mindermann T, Wilson CB: Pediatric pituitary adenomas. Neurosurgery 1995;36:259–269.
4.
Oberfield SE, Nino M, Riddick L, Pang S, Nagel M, Khandji A, Kairam R, Levine LS: Combined bromocriptine and GH treatment in GH-deficient children with macroprolactinoma in situ. J Clin Endocrinol Metab 1992;75:87–90.
5.
Tyson D, Reggiardo D, Sklar C, David R: Prolactin-secreting macroadenomas in adolescents. Response to bromocriptine therapy. Am J Dis Child 1993;147:1057–1061.
6.
Liuzzi A, Dallabonzana D, Oppizzi G, Verde GG, Cozzi R, Chiodini P, Luccarelli G: Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 1985;313:656–659.
7.
Molitch ME, Elton RC, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO, the Bromocriptine study group: Bromocriptine as primary therapy for prolactin-secreting macroadenomas: Results of a prospective multicenter study. J Clin Endocrinol Metab 1985;60:698–705.
8.
Thorner MO, Flückiger E, Carne DB: Bromocriptine: A clinical and pharmacological review. New York, Raven Press, 1980.
9.
Bevan JS, Webster J, Burke CW, Scanlon MF: Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992;13:221–235.
10.
Ferrari C, Barbieri C, Caldara R, Mucci M, Codecasa F, Paracchi A, Romano C, Boghen M, Dubini A: Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J Clin Endocrinol Metab 1986;63:941–945.
11.
Mattei AM, Ferrari C, Baroldi P, Cavioni V, Paracchi A, Galparoli C, Romano C, Spellecchia D, Gerevini G, Crosignani PG: Prolactin lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients. J Clin Endocrinol Metab 1988;66:193–198.
12.
Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G: Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 1997;82:3574–3579.
13.
Colao A, Loche S, Cappa M, di Sarno A, Landi ML, Sarnacchiaro F, Facciolli G, Lombardi G: Prolactinomas in children and adolescents. Clinical presentation and long-term follow up. J Clin Endocrinol Metab 1998;83:2777–2780.
14.
Howlett TA, Wass AH, Grossman A, Plowman PN, Charlesworth M, Touzel R, Rees LH, Savage MO, Besser GM: Prolactinomas presented as primary amenorrhea and delayed or arrested puberty: Response to medical therapy. Clin Endocrinol 1994;30:131–140.
15.
Sack J, Friedman E, Tadmor R, Saher A, Katznelson D: Growth and puberty arrest due to prolactinoma. Acta Paediatr Scand 1984;73:863–867.
16.
Oberfield SE, Nino M, Riddich L, Pang S, Nagel M, Khandji A, Kairam R, Levine LS: Combined bromocriptine and growth hormone (GH) treatment in GH deficient children with macroprolactinoma in situ. J Clin Endocrinol Metab 1992;75:87–90.
17.
Cesario F, Borretta G, Meineri I, Muratori M, Pizzocaro A, Beck-Peccoz P: Combined cabergoline and rhGH treatment of an adolescent with a macroprolactinoma causing GH deficiency. J Pediatr Endocrinol Metab 1997;10:231–236.
18.
Angyal EA, Lee HJ, Wolansky LJ, Koenigsberger MR, Nathanson D, Zimmer AE: Prolactinoma invasion of superior ophthalmic vein: CT and MR findings. J Comput Assist Tomogr 1993;17:964–966.
19.
Bevan JS, Davis RE: Cabergoline: An advance in dopaminergic therapy. Clin Endocrinol 1994;411:709–712.
20.
Pontiroli AE, Cammelli L, Baroldi P, Pozza G: Inhibition of basal and metoclopramide-induced prolactin release by cabergoline, an extremely long-acting dopaminergic drug. J Clin Endocrinol Metab 1987;65:1057–1059.
21.
Ferrari C, Paracchi A, Mattei AM, de Vincentiis S, D’Alberton A, Crosignari PG: Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Edocrinol (Copenh) 1992;126:489–494.
22.
Biller BMK, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, Schoenfelder JR, Klibanski A: Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996;81:2338–2343.
23.
Molitch ME, Thorner MO, Wilson C: Management of prolactinomas. J Clin Endocrinol Metab 1997;82:996–1000.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.